Vimarsana
Biggest News Aggregation in the World

Linzess Constella News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Linzess Constella. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Linzess Constella Today - Breaking & Trending Today

AbbVie Reports First-Quarter 2024 Financial Results - Vimarsana News

AbbVie Reports First-Quarter 2024 Financial Results

Reports First-Quarter Diluted EPS of $0.77 on a GAAP Basis, an Increase of 492.3 Percent; Adjusted Diluted EPS of $2.31, a Decrease of 6.1 Percent; These...

AbbVie Reports Full-Year and Fourth-Quarter 2023 Financial Results - Vimarsana News

AbbVie Reports Full-Year and Fourth-Quarter 2023 Financial Results

Reports Full-Year Diluted EPS of $2.72 on a GAAP Basis, a Decrease of 59.0 Percent; Adjusted Diluted EPS of $11.11, a Decrease of 19.3 Percent; These Results...

Comparing Cosmo Pharmaceuticals (OTC:CMOPF) and AbbVie (NYSE:ABBV) - Vimarsana News

Comparing Cosmo Pharmaceuticals (OTC:CMOPF) and AbbVie (NYSE:ABBV)

Cosmo Pharmaceuticals (OTC:CMOPF – Get Free Report) and AbbVie (NYSE:ABBV – Get Free Report) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, dividends, earnings and risk. Insider and Institutional Ownership 70.2% of AbbVie shares are […]

Analyzing AbbVie (NYSE:ABBV) & PT Kalbe Farma Tbk. (OTCMKTS:PTKFF) - Vimarsana News

Analyzing AbbVie (NYSE:ABBV) & PT Kalbe Farma Tbk. (OTCMKTS:PTKFF)

AbbVie (NYSE:ABBV – Get Free Report) and PT Kalbe Farma Tbk. (OTCMKTS:PTKFF – Get Free Report) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, dividends, profitability, analyst recommendations, valuation, earnings and institutional ownership. Analyst Recommendations This is a breakdown of […]

AbbVie Reports Third-Quarter 2023 Financial Results - Vimarsana News

AbbVie Reports Third-Quarter 2023 Financial Results

Reports Third-Quarter Diluted EPS of $1.00 on a GAAP Basis, a Decrease of 54.8 Percent; Adjusted Diluted EPS of $2.95, a Decrease of 19.4 Percent; These...